FOXP4-AS1 May Be a Potential Prognostic Biomarker in Human Cancers: A Meta-Analysis and Bioinformatics Analysis

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Jun 20

PMID 35719909

Authors

Guangming Zhang

Yongfeng Wang

Xiaoyong Han

Tingting Lu

Liangyin Fu

Haojie Jin

Kehu Yang

Hui Cai

Affiliations

Soon will be listed here.

Abstract

Background: Cancer is one of the leading causes of death worldwide. Early diagnosis can significantly lower cancer-related mortality. Studies have shown that the lncRNA Forkhead box P4 antisense RNA 1 (FOXP4-AS1) is aberrantly expressed in various solid tumors. A meta-analysis was performed to evaluate the correlation of FOXP4-AS1 with the prognosis of cancer patients and determine the clinical value of FOXP4-AS1 as a potential diagnostic marker.

Methods: Correlational studies from the Web of Science, Embase, OVID, Cochrane and PubMed databases were screened (up to April 1, 2021). Meta-analysis was performed using Stata SE12.0 software.

Results: Eleven original studies with 1,332 patients who were diagnosed with a solid cancer (nasopharyngeal carcinoma, hepatocellular carcinoma, colorectal cancer, gastric cancer, osteosarcoma, mantle cell lymphoma, prostate cancer, and pancreatic ductal adenocarcinoma) were included in the meta-analysis. High expression of FOXP4-AS1 was correlated with poor overall survival (OS) (HR = 1.77, 95% CI 1.29-2.44, < 0.001) and shorter disease-free survival (DFS) (HR = 1.66, 95% CI 1.01-2.72, = 0.044). Subgroup analysis based on sample size, follow-up time and Newcastle-Ottawa Scale (NOS) score revealed significant differences between FOXP4-AS1 levels and OS ( < 0.05). However, the expression level of FOXP4-AS1 was not significantly correlated with the OS of gastric cancer patients ( = 0.381). High expression of FOXP4-AS1 was predictive of a larger tumor size (OR = 3.82, 95% CI 2.3-6.3, < 0.001).

Conclusions: Overexpression of FOXP4-AS1 correlates with poor prognosis of cancer patients, and is a potential prognostic biomarker and therapeutic target.

Systematic Review Registration: PROSPERO, identifier CRD42021245267.

Citing Articles

FOXP4-AS1 promotes CD8 T cell exhaustion and esophageal cancer immune escape through USP10-stabilized PD-L1.

Shen G, Zhang Y, Huang R, Huang Z, Yang L, Chen D Immunol Res. 2024; 72(4):766-775.

PMID: 38687433 DOI: 10.1007/s12026-024-09482-9.

Decoding the regulatory landscape of lncRNAs as potential diagnostic and prognostic biomarkers for gastric and colorectal cancers.

Zabeti Touchaei A, Vahidi S, Samadani A Clin Exp Med. 2024; 24(1):29.

PMID: 38294554 PMC: 10830721. DOI: 10.1007/s10238-023-01260-5.

Non-coding RNAs and gastrointestinal cancers prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies.

Zha B, Luo Y, Kamili M, Zha X Front Oncol. 2023; 13:1193665.

PMID: 37546412 PMC: 10399243. DOI: 10.3389/fonc.2023.1193665.

A pan-cancer analysis of the prognostic value of long non-coding RNA LINC00662 in human cancers.

Zhang G, Wu B, Fu L, Liu B, Han X, Wang J Front Genet. 2022; 13:1063119.

PMID: 36568401 PMC: 9773142. DOI: 10.3389/fgene.2022.1063119.

LINC00958 may be a new prognostic biomarker in various cancers: A meta-analysis and bioinformatics analysis.

Zhang H, Zhang G, Zhang F, Yang X, Li E, Wang B Front Genet. 2022; 13:998442.

PMID: 36437914 PMC: 9691855. DOI: 10.3389/fgene.2022.998442.

References

Tao H, Shen J, Hou Z, Chen S, Su Y, Fang J . lncRNA FOXP4‑AS1 predicts poor prognosis and accelerates the progression of mantle cell lymphoma through the miR‑423‑5p/NACC1 pathway. Oncol Rep. 2021; 45(2):469-480. PMC: 7757101. DOI: 10.3892/or.2020.7897. View

Han L, Wang B, Wang R, Wang Z, Gong S, Chen G . Prognostic and Clinicopathological Significance of Long Non-coding RNA PANDAR Expression in Cancer Patients: A Meta-Analysis. Front Oncol. 2019; 9:1337. PMC: 6901660. DOI: 10.3389/fonc.2019.01337. View

Li Y, Li T, Yang Y, Kang W, Dong S, Cheng S . YY1-induced upregulation of FOXP4-AS1 and FOXP4 promote the proliferation of esophageal squamous cell carcinoma cells. Cell Biol Int. 2020; 44(7):1447-1457. DOI: 10.1002/cbin.11338. View

Huang J, Li H, Zhu J, Song J, Zhang X, Gong P . SRPK1/AKT axis promotes oxaliplatin-induced anti-apoptosis via NF-κB activation in colon cancer. J Transl Med. 2021; 19(1):280. PMC: 8243872. DOI: 10.1186/s12967-021-02954-8. View

Liang J, Wang D, Qiu G, Zhu X, Liu J, Li H . Long Noncoding RNA FOXP4-AS1 Predicts Unfavourable Prognosis and Regulates Proliferation and Invasion in Hepatocellular Carcinoma. Biomed Res Int. 2021; 2021:8850656. PMC: 7870313. DOI: 10.1155/2021/8850656. View

Li J, Lian Y, Yan C, Cai Z, Ding J, Ma Z . Long non-coding RNA FOXP4-AS1 is an unfavourable prognostic factor and regulates proliferation and apoptosis in colorectal cancer. Cell Prolif. 2016; 50(1). PMC: 6529074. DOI: 10.1111/cpr.12312. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Zhong X, Tao Y, Chang J, Zhang Y, Zhang H, Wang L . Prognostic Signature of Immune Genes and Immune-Related LncRNAs in Neuroblastoma: A Study Based on GEO and TARGET Datasets. Front Oncol. 2021; 11:631546. PMC: 7985261. DOI: 10.3389/fonc.2021.631546. View

Li Y, Cao L, Zhang Z, Hou L, Qin Y, Hui X . Reporting and methodological quality of COVID-19 systematic reviews needs to be improved: an evidence mapping. J Clin Epidemiol. 2021; 135:17-28. PMC: 8313077. DOI: 10.1016/j.jclinepi.2021.02.021. View

10.

Zhang Y, Tang L . The Application of lncRNAs in Cancer Treatment and Diagnosis. Recent Pat Anticancer Drug Discov. 2018; 13(3):292-301. DOI: 10.2174/1574892813666180226121819. View

11.

Yao L, Sun R, Chen Y, Wang Q, Wei D, Wang X . The quality of evidence in Chinese meta-analyses needs to be improved. J Clin Epidemiol. 2016; 74:73-9. DOI: 10.1016/j.jclinepi.2016.01.003. View

12.

Li J, Gao W, Punja S, Ma B, Vohra S, Duan N . Reporting quality of N-of-1 trials published between 1985 and 2013: a systematic review. J Clin Epidemiol. 2016; 76:57-64. DOI: 10.1016/j.jclinepi.2015.11.016. View

13.

Zhou H, Shen Q, Fu J, Jiang F, Wang L, Wang Y . Analysis of lncRNA UCA1-related downstream pathways and molecules of cisplatin resistance in lung adenocarcinoma. J Clin Lab Anal. 2020; 34(8):e23312. PMC: 7439354. DOI: 10.1002/jcla.23312. View

14.

Yang L, Ge D, Chen X, Qiu J, Yin Z, Zheng S . FOXP4-AS1 participates in the development and progression of osteosarcoma by downregulating LATS1 via binding to LSD1 and EZH2. Biochem Biophys Res Commun. 2018; 502(4):493-500. DOI: 10.1016/j.bbrc.2018.05.198. View

15.

Xiong J, Wu L, Huang L, Wu C, Liu Z, Deng W . LncRNA FOXP4-AS1 Promotes Progression of Ewing Sarcoma and Is Associated With Immune Infiltrates. Front Oncol. 2021; 11:718876. PMC: 8577041. DOI: 10.3389/fonc.2021.718876. View

16.

Akhade V, Pal D, Kanduri C . Long Noncoding RNA: Genome Organization and Mechanism of Action. Adv Exp Med Biol. 2017; 1008:47-74. DOI: 10.1007/978-981-10-5203-3_2. View

17.

Zhao J, Yang T, Li L . LncRNA FOXP4-AS1 Is Involved in Cervical Cancer Progression via Regulating miR-136-5p/CBX4 Axis. Onco Targets Ther. 2020; 13:2347-2355. PMC: 7094166. DOI: 10.2147/OTT.S241818. View

18.

Zhong L, Zhou J, He X, He B, Zhou X, Zhu J . Long non-coding RNA FOXP4-AS1 acts as an adverse prognostic factor and regulates proliferation and apoptosis in nasopharyngeal carcinoma. Eur Rev Med Pharmacol Sci. 2020; 24(15):8008-8016. DOI: 10.26355/eurrev_202008_22484. View

19.

Ng L, Poon R, Pang R . Biomarkers for predicting future metastasis of human gastrointestinal tumors. Cell Mol Life Sci. 2013; 70(19):3631-56. PMC: 11113832. DOI: 10.1007/s00018-013-1266-8. View

20.

Prattapong P, Ngernsombat C, Aimjongjun S, Janvilisri T . CRISPR/Cas9-mediated double knockout of SRPK1 and SRPK2 in a nasopharyngeal carcinoma cell line. Cancer Rep (Hoboken). 2020; 3(2):e1224. PMC: 7941449. DOI: 10.1002/cnr2.1224. View